The Shockwave Team
The true strength of Shockwave is a remarkable team of talented
individuals with experience, creativity and tenacity. A strong leadership team is reflective
of our dedication to developing technologies and applications that enable interventionalist to
raise the standard of how advanced cardiovascular disease is treated.
Executive Team
Doug Godshall
President & CEO
Dan Puckett
Chief Financial Officer
Isaac Zacharias
Chief Commercial Officer
Keith D. Dawkins M.D.
Chief Medical Officer
Hajime Tada
General Counsel
Beaux Alexander
VP, Clinical Affairs
Meg Carr
VP, Regulatory Affairs
Robert Fletcher
VP, Marketing
Cathy Harnett
Director, Human Resources
Debbie Kaster
Head of Investor Relations
Peter Nowakowski
VP, Quality
Mike Maszy
VP, Operations
Trinh Phung
VP, Finance
Patrick Stephens
VP, Research & Development
Rob Williamson
VP, Sales
Board of Directors
Ray Larkin
Chairman & Independent Director
Antoine Papiernik
Sofinnova Partners
Colin Cahill
San Francisco Giants
Doug Godshall
President & Chief Executive Officer
Shockwave Medical
Frederic Moll, M.D.
Auris Health
Jay Watkins
De Novo Ventures
Laura Francis
SI-BONE
Maria Sainz
Aegea Medical, Inc.
Ready to Make Waves with Shockwave IVL?
We're excited about IVL's potential in aortic stenosis, too!
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Get Crackin with Shockwave IVL Today
Wow - you're ready to start cracking, aren't you?
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
IT’S TIME TO
GET CRACKING
COUNTDOWN TO CAD III PRESENTATION
Caution: Investigational device. Limited by Federal (U.S.) law to investigational use.
ISI: https://shockwavemedical.com/important-safety-information-coronary/